argenx SE (ARGX) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

H.C. Wainwright Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $717
Moomoo News11:32 ET · Ratings
JMP Securities Maintains Market Outperform on Argenx, Raises Price Target to $696
BenzingaJan 14 08:52 ET · Ratings
A Quick Look at Today's Ratings for Argenx SE(ARGX.US), With a Forecast Between $696 to $772
Moomoo NewsJan 14 08:00 ET · Ratings
Argenx Se: Strong Financial Performance and Promising Growth Prospects Justify Buy Rating
TipRanksJan 13 20:09 ET · Ratings
Express News | Argenx SE : Wedbush Raises Target Price to $715 From $665
ReutersJan 13 09:31 ET
Express News | Argenx SE : Jefferies Raises Target Price to $772 From $750
ReutersJan 13 08:14 ET

Comments

Money Thrill

Nov 12, 2024 03:38

European Morning news [MarketDevil]

$argenx SE (ARGX.US)$ (ABM FN) China's regulator has approved the Supplemental Biologics License Application for Vyvgart Hytrulo for the treatment of adults suffering from CIDP. The biotech company announced this after the close.
This approval followed the Adhere study.This concerns an injection of 1,000 milligrams that can be administered once a week. About 50,000 people in China suffer from CIDP.
“It is the first and only treatment approved in China for CIDP,”...

Money Thrill

Nov 2, 2024 14:19

European News from journal HLN (LeatestNewsJournal)

$argenx SE (ARGX.US)$ Last quarter, the company recorded a net profit of 91.4 million euros, compared to a net loss of 72.6 million euros in the same period last year. After nine months there is a net profit of 58.9 million euros against a net loss of 195.9 million euros.
The difference between the operational results and the net result is mainly made up of the financial results and the taxes on the result. At the end of September, Argenx still h...

1

Meltyy

Jun 25, 2024 07:02

🔔 FDA PDUFA Update…

🔥 3 PDUFA decisions this week! 👇
📌 This week’s PDUFAs:
$Merck & Co (MRK.US)$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma (VRNA.US)$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab (GMAB.US)$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co (MRK.US)$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...